TABLE 2.
Cost inputs and utilities.
| Variable | Baseline value (range) | References | Distribution (parameters) |
|---|---|---|---|
| Body surface area, m2 | 1.72 | Chen X. et al. (2019) | |
| Drug cost, $/cycle | |||
| Sintilimab | 303.85 (243.08–364.62) | Local charge | Gamma |
| Gemcitabine | 9.63 (7.7–11.56) | Local charge | Gamma |
| Cisplatin | 11.61 (9.29–13.93) | Local charge | Gamma |
| Concurrent cisplatin | 15.84 (12.38–18.57) | Local charge | Gamma |
| Antiemetic drugs | 65.55 (52.44–78.66) | Local charge | Gamma |
| Radiotherapy | 9,633.84 (7,707.07–11560.61) | Local charge | Gamma |
| Preparation of radiotherapy | 681.52 (545.22–817.83) | Local charge | Gamma |
| Main subsequent therapy, $/cycle | |||
| Chemotherapy | 35.29 (28.23–42.35) | Local charge | Gamma |
| Immunotherapy | 417.47 (333.98–500.96) | Local charge | Gamma |
| Surgery | 4,635.85 (3,708.68–5,563.02) | Local charge | Gamma |
| 2nd radiotherapy | 5,081.44 (4,065.15–6,097.73) | Local charge | Gamma |
| Targeted therapy | 558.32 (446.66–669.98) | Local charge | Gamma |
| Supported care | 52.5 (42–63) | Local charge | Gamma |
| Subsequent therapy in Sintilimab group | 300.02 (240.02–360.02) | Local charge | Gamma |
| Subsequent therapy in standard therapy group | 540.6 (432.48–648.72) | Local charge | Gamma |
| Expenditures on main adverse events, $ | |||
| Anaemia | 508.2 (406.56–609.84) | Wu et al. (2018) | Gamma |
| Leukopenia | 406.37 (325.10–487.64) | Shi et al. (2018) | Gamma |
| Nausea | 44.3 (35.44–53.16) | Wu et al. (2012) | Gamma |
| Mucositis | 19.94 (15.95–23.93) | Local charge | Gamma |
| Anorexia | 26 (20.8–31.2) | Local charge | Gamma |
| Neutropenia | 406.37 (325.10–487.64) | Local charge | Gamma |
| Dermatitis | 16.64 (13.31–19.97) | Local charge | Gamma |
| Fatigue | 110.3 (88.24–132.36) | Wu et al. (2018) | Gamma |
| Vomiting | 44.3 (35.44–53.16) | Wu et al. (2012) | Gamma |
| Rash | 59.57 (47.66–71.48) | Local charge | Gamma |
| Hospitalization $/per cycle | 126.78 (101.43–152.14) | Local charge | Gamma |
| Laboratory $/per cycle | 74.85 (59.88–89.82) | Local charge | Gamma |
| Follow-up test $/per time | 378.12 (302.5–453.74) | Local charge | Gamma |
| PICC per time | 134.15 (107.32–160.98) | Local charge | Gamma |
| Discount rate | 0.05 | Wu et al. (2018) | - |
| Utility | - | ||
| Utility EFS | 0.76 (0.61–0.91) | She et al. (2022) | Beta |
| Utility PD | 0.57 (0.46–0.68) | She et al. (2022) | Beta |
| Death | 0 | She et al. (2022) | Beta |
Abbreviation: EFS, Event-free survival; PD, progressive disease; PICC, peripherally inserted central catheters.